Navigation Links
YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
Date:12/6/2010

al Officer and Vice President, Regulatory Affairs, Dr. Gregg Smith, Vice President, Australian Operations and Dr. Chris Burns, Director, Research, YM BioSciences Australia.

Analysts and professional investors may also participate in the meeting by conference call. A webcast of the meeting will be available on YM's website: www.ymbiosciences.com.

Meeting/Conference Call Details: DATE: December 6, 2010 TIME: 12:30 pm Eastern Time DIAL IN NUMBER: (647) 427-7450 or (888) 231-8191 MEETING LOCATION: Hilton Orlando, Lake Sheen A Room

About CYT387:

CYT387 is an inhibitor of the kinase enzymes JAK1 and JAK2, which have been implicated in a family of hematological conditions known as myeloproliferative neoplasms, including myelofibrosis, and as well in numerous other disorders including indications in hematology, oncology and inflammatory diseases. Myelofibrosis is a chronic debilitating disease in which a patient's bone marrow is replaced by scar tissue and for which treatment options are limited or unsatisfactory. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CYT387 for the treatment of myelofibrosis.

YM BioSciences retains the global commercialization rights to CYT387.

About YM BioSciences

YM BioSciences Inc. is a drug development company advancing three clinical-stage products: CYT387, a small molecule, dual inhibitor of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).

CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis with positive interim safety and activity data reported at the American Society of Hematology (ASH
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
2. Ardea Biosciences to Present at Two Upcoming Investor Conferences
3. YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
4. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
5. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
6. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
7. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
8. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
9. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
10. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
11. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500â„¢
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security LLC ... to develop and deliver a state-of-the-art laser system ... facility (ELI Beamlines), under construction in the Czech ... performance, the laser system, called the " High ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Global Chelating ... About Chelating Agent A chelating ... covalent bonds with metal ions, thereby forming a ... some metal-ions have on chemical processes, formulations, and ...
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... 2014  ARCH Venture Partners, one of the ... development of seed and early-stage advanced technology companies, ... with more than $400 million in subscriptions. ARCH ... target by more than $150 million. ... and potential of our approach to finding and ...
Breaking Biology Technology:LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... , PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: ... a voluntary recall of five lots and voluntary market withdrawal ... ® . Shire is taking this action because some Daytrana ... meet their release liner removal specification, and as a result, ...
... , , COLUMBIA, Md., Dec. 2 ... it intends to release the results of its fourth quarter and ... Eastern Time (ET). Following the release, at 4:45 p.m. ET ... investors. All interested parties may listen to the call live ...
... , NEW YORK, Dec. 2 Nearly 600 ... to explore novel development approaches and innovative funding strategies at ... FasterCures, the Washington-based center of the Milken Institute, ... needed to turn a scientific discovery into an accessible therapy. ...
Cached Biology Technology:Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2
(Date:8/28/2014)... PA, August 28, 2014 Dyslexia, the most ... is a neurological reading disability that occurs when ... language don,t function normally. , The use of ... brain activity is disrupted in dyslexia. However, most ... number of brain regions, leaving a gap in ...
(Date:8/28/2014)... of new roads will be built worldwide by 2050. ... wildernesses, where they bring an influx of destructive loggers, ... study has created a ,global roadmap, for prioritising road ... competing demands of development and environmental protection. , The ... that natural importance of ecosystems and a ,road-benefits, layer ...
(Date:8/28/2014)... . Cars, planes ... of sophisticated assembly lines. Mobile assembly carriers, on to which ... assembly lines. In the case of a car body, the ... a precise spatial and chronological sequence, resulting in a complete ... of such an assembly line at molecular level has been ...
Breaking Biology News(10 mins):Dyslexic readers have disrupted network connections in the brain 2Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3Nanoscale assembly line 2Nanoscale assembly line 3
... in Nature Cell Biology , scientists from the ... Regenerative Medicine Institute (ARMI) have revealed new insights into ... In an early mammalian embryo, just 8-cells large, the ... something that would determine whether the embryo survived ...
... Colo., USA Locations studied for this month,s posting ... Llaima volcano, Chile; the Mississippi Fan (Gulf of Mexico); ... the Atlas Mountains of Morocco; the East Antarctic Ice ... Regab pockmark, offshore Africa; the Siberian Traps; the eastern ...
... significant signaling network in a tiny organism that,s big ... how a remarkably fast-growing organism conducts its metabolic business ... microbe Synechococcus , which turns sunlight into useful ... Pacific Northwest National Laboratory glimpsed key chemical events, known ...
Cached Biology News:Your first hug: How the early embryo changes shape 2Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 2Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 3Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 4Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 5Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 6Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 7Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 8Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 9Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 10Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 11Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 12Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 13Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 14Offshore pockmarks, Wax Lake Delta, Cabo de Gata, the Siberian Traps: Geology covers the world 15Scientists capture 'redox moments' in living cells 2Scientists capture 'redox moments' in living cells 3
... are used to study co-translational and ... events such as signal peptide cleavage, ... can be examined by the translation ... in the presence of these microsomal ...
Polio component type I...
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
... LC Sciences provides a comprehensive ... small regulatory/functional RNA embedded within non-coding ... technology and proprietary probe design, which ... detection of small RNAs (1). This ...
Biology Products: